Merck & Co Inc
MRK
View Detailed Chart
121.930USD
+2.180+1.82%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
303.28BMarket Cap
16.75P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.82%
5 Days
+10.57%
1 Month
+12.00%
6 Months
+53.49%
Year to Date
+15.84%
1 Year
+38.48%
View Detailed Chart
TradingKey Stock Score of Merck & Co Inc
Currency: USD Updated: 2026-02-06Key Insights
Merck & Co Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 120.78.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Merck & Co Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
49°C
Very Low
Very High
Positive
Merck & Co Inc Highlights
StrengthsRisks
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.01B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.
Fairly Valued
The company’s latest PE is 16.75, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.99B shares, decreasing 2.82% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 51.41K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.02.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
120.780
Target Price
+0.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Merck & Co Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Merck & Co Inc Info
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Ticker SymbolMRK
CompanyMerck & Co Inc
CEODavis (Robert M)
Websitehttps://www.merck.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68750.820
-1219.310 (-1.74%)
282.580
+22.390 (+8.61%)
2042.060
-9.670 (-0.47%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
